Full Report

Know the Business

Centene is the nation's largest government-sponsored managed care company, collecting $195B in premiums from Medicaid, Medicare PDP, and ACA Marketplace contracts and paying out 92 cents of every dollar in medical claims. The business runs on thin margins amplified by massive scale — operating income swings of 100 basis points on a $175B premium base move $1.7B of pretax profit. The market is underestimating how quickly CNC can normalize margins after the FY2025 goodwill impairment and Medicaid redetermination headwinds, and overestimating the permanence of elevated medical cost trends.

How This Business Actually Works

Centene's revenue engine is straightforward: state and federal governments pay fixed per-member-per-month (PMPM) premiums to manage healthcare for low-income and elderly populations. Centene then pays providers for the care those members consume.

Parser Error: syntax error at or near "union"

LINE 2: ....7 as hbr, 12.5 as members_m, 2025 as yr_sort order by yr_sort union all
                                                                          ^

LINE 2: ....7 as hbr, 12.5 as members_m, 2025 as yr_sort order by yr_sort union all
                                                                          ^

The profit mechanism: Centene earns the spread between PMPM premiums and medical costs (the Health Benefits Ratio, or HBR). Every 100bp improvement in HBR on $172B of premiums drops $1.7B to pretax income. SG&A runs at 7.4% — industry-best efficiency driven by scale — leaving operating margins in the 1-3% range in normal years.

Three things drive incremental profit: (1) rate adequacy — whether states raise PMPM rates fast enough to match medical cost inflation, (2) mix shift — Marketplace and PDP carry better margins than Medicaid, and (3) SG&A leverage — spreading fixed costs over a growing premium base.

The cost structure is almost entirely variable: 92% medical costs, 7.4% SG&A, leaving under 1% for everything else. This makes Centene a razor-thin margin business where execution on medical management, rate advocacy, and fraud prevention determines the difference between a great year and a disaster.

The Playing Field

The peer set reveals Centene's paradox: second-largest US health insurer by revenue ($195B) but valued at $26B — a fraction of UnitedHealth ($410B) despite being half its revenue size. The discount reflects three things. First, UNH earns diversified income through Optum (care delivery + PBM + analytics), while CNC is a pure managed care pass-through business. Second, CNC's government-heavy mix (57% Medicaid) carries lower margins than commercial insurance. Third, the FY2025 goodwill impairment and Medicaid margin pressure have cratered investor confidence.

Molina is the closest comp — also Medicaid-focused, similar SG&A efficiency — and trades at 15x earnings vs CNC's ~25x on depressed FY2025 adjusted earnings. If CNC normalizes to guidance ($3.40+ EPS in FY2026), the forward P/E compresses to ~16x, roughly in line with Molina.

Is This Business Cyclical?

Managed Medicaid is countercyclical by design — enrollment rises during recessions as more people qualify for government assistance. Centene's Medicaid membership grew from 4.4M in 2010 to a peak of 15.7M post-COVID (2023), then dropped to 12.5M through redeterminations.

The real cycle hits through three channels:

Rate lag. Medical costs rise immediately; state Medicaid rate increases arrive 6-18 months later. FY2025's HBR of 91.9% vs FY2024's 88.3% captures this lag — behavioral health, home health, and specialty pharmacy costs surged while rates were still catching up. Composite rates closed FY2025 at +5.5%, and management expects mid-4% for FY2026.

Membership churn. Post-COVID redeterminations stripped 3.2M Medicaid members from CNC between March 2023 and December 2025. The OBBBA (July 2025) adds work requirements and more frequent eligibility checks, likely shedding additional lower-acuity members and raising per-member morbidity.

Regulatory whiplash. Enhanced APTCs expired end of 2025, expected to shrink Marketplace enrollment from 5.5M to ~3.5M in Q1 2026 (already tracking to 3.58M). CNC repriced 95% of Marketplace membership in Q3 2025 to compensate.

The business survived every cycle test: revenue never declined year-over-year even as operating income fluctuated dramatically. The FY2025 GAAP loss (-$6.7B) was entirely driven by a non-cash $6.7B goodwill impairment — adjusted operating income was positive.

The Metrics That Actually Matter

HBR is the only metric that matters for quarters. A 50bp HBR improvement on $172B of premiums adds $860M pretax. Q1 FY2026 HBR of 87.3% is 360bp better than FY2025's 91.9%, signaling aggressive margin recovery. Medicaid HBR improved to 93.1% (down 50bp YoY) — third consecutive quarter of progress.

SG&A ratio is the structural advantage. At 7.4%, CNC runs leaner than UNH (13.3%), ELV (11.2%), and HUM (11.8%). Only Molina (7.2%) matches it. This efficiency comes from scale: spreading fixed costs over $175B of premium revenue.

Adjusted EPS strips the signal from the noise. GAAP EPS of -$13.53 in FY2025 is meaningless for valuation — it's the $6.7B goodwill impairment. Adjusted EPS of $2.08 shows the underlying business still earned money. The Q1 FY2026 beat ($3.37 vs internal expectations) and raised full-year guidance (over $3.40) suggest FY2026 adjusted EPS could approach $6-7.

What I'd Tell a Young Analyst

Watch three things: Medicaid HBR trajectory quarter by quarter (must keep improving toward 90%), Marketplace membership retention post-APTC expiration (3.5M is the floor the company priced for), and whether the Q1 FY2026 earnings beat ($3.37, nearly $0.50 above internal expectations) is the start of a multi-quarter beat cycle or a one-off from favorable flu season timing.

The market treats CNC like a broken company because of the $6.7B goodwill impairment headline and the FY2025 GAAP loss. But the impairment was non-cash and reflected overpayment for WellCare in 2020, not deterioration of the core Medicaid franchise. Adjusted operating cash flow was $5.1B in FY2025 — the business generates real cash.

The biggest risk is not medical costs — those are cyclical and rates eventually catch up. The risk is political: the OBBBA's Medicaid work requirements and provider tax changes (effective 2028) could structurally shrink the Medicaid managed care TAM. If Congress cuts Medicaid funding faster than CNC can shift members to Medicare D-SNPs and Marketplace, the growth engine stalls. That transition — from Medicaid-first to multi-product — is the strategic bet Sarah London is making with the new leadership structure (Dan Finke for Medicaid/Commercial, Michael Carson for Medicare/Specialty).

The Numbers

Centene trades at $53.69 on $195B of revenue — a $26B market cap for the second-largest US health insurer. The stock is priced for permanent margin impairment after the FY2025 goodwill write-down, but normalized earnings are recovering faster than the market expects. The single metric most likely to rerate this stock is the Medicaid HBR — if Q1 FY2026's 93.1% trajectory holds through the year, adjusted EPS of $6+ is achievable by FY2027, implying the stock trades at under 9x normalized earnings.

Revenue & Earnings Power — 20-Year View

Centene has never had a year of revenue decline. From $1.2B in FY2005 to $195B in FY2025 — a 30% CAGR driven by organic Medicaid wins and transformative M&A (Health Net 2016, Fidelis 2018, WellCare 2020).

The FY2025 operating loss of -$7.6B is entirely the $6.7B goodwill impairment plus $513M Magellan impairment. Adjusted operating income was approximately $1.0B — depressed but positive.

Pre-impairment operating margins averaged 2.0% over FY2016-2024. The managed care business operates on razor-thin margins by design — the profit is in the scale.

Quarterly Revenue Momentum

Revenue growth accelerated from 6% in FY2024 to 19% in FY2025, driven by PDP premium yield (IRA-driven shift in cost-sharing), Marketplace membership growth (+26% YoY), and Medicaid rate increases. Q1 FY2026 revenue of $49.9B continues the trend.

Cash Generation — Are the Earnings Real?

FY2024's operating cash flow of $154M was an aberration — $4.3B of receivables growth (mostly Marketplace risk adjustment timing) drained working capital. FY2025's $5.1B normalized the picture. Over FY2020-2025, cumulative operating cash flow totaled $29.3B against cumulative net income of $3.9B — demonstrating that even in the loss year, the business throws off real cash.

Capex runs at under 0.5% of revenue ($767M on $195B) — this is an asset-light business. FCF of $4.3B in FY2025 represents a 16% FCF yield on the current $26.4B market cap.

Capital Allocation

Centene has never paid a dividend. Capital allocation shifted dramatically post-WellCare: FY2022-2024 saw $7.9B in buybacks (shares fell from 582M to 492M), reducing diluted share count by 15%. FY2025 buybacks slowed to $475M, and 2026 guidance includes zero buybacks — cash is being redirected to debt reduction and margin recovery investments.

SBC runs at $204M (FY2025), or about 0.1% of revenue — immaterial dilution.

Balance Sheet Health

Total long-term debt of $17.4B against equity of $20.0B (debt-to-capital 46.5% at year-end, improved to 43.2% by Q1 FY2026). The equity decline from FY2024's $26.4B to FY2025's $20.0B is entirely the goodwill impairment write-through. The balance sheet is strained but manageable — interest expense of $678M is well-covered by $5.1B operating cash flow (7.5x coverage).

Goodwill fell from $17.6B to $10.8B after the impairment. Remaining goodwill of $10.8B against $20.0B equity means intangible-adjusted book value is thin, but for a managed care company with no hard assets, this is typical.

Valuation — Historical Context

On FY2025 adjusted EPS of $2.08, the stock trades at 25.8x — expensive on trough earnings. On the raised FY2026 guidance of over $3.40, forward P/E is ~15.8x. If EPS normalizes toward $6+ by FY2027 (pre-impairment FY2024 level was $7.17), the stock is under 9x forward.

The 10-year median adjusted P/E is approximately 18x. At 18x on $6 normalized EPS = $108. At 15x (Medicaid peer discount) = $90. At 10x (distressed pricing) = $60, roughly where it trades today.

Peer Comparison

Centene's 16.3% FCF yield dwarfs every peer. Price-to-revenue of 0.14x is the lowest in the group by a wide margin — the market assigns almost no value to $195B of revenue. This reflects the depressed-earnings narrative, but if margins normalize, the rerating potential is substantial.

Fair Value & Scenario

Bear ($34): Medicaid margins don't recover, Marketplace shrinks further, medical cost trends persist. Market applies distressed 10x on guided $3.40 EPS.

Base ($82): HBR normalizes to ~89% by FY2027, Medicaid rates catch up, Marketplace repricing holds. 15x on $5.50 normalized EPS — peer-median multiple on recovered earnings.

Bull ($126): Full margin recovery to FY2024 levels ($7 EPS), D-SNP growth accelerates, market re-rates to historical 18x.

The numbers confirm that Centene is a massive business generating substantial cash flow through a period of temporary margin compression. The FY2025 goodwill impairment is backward-looking noise. What the popular narrative misses is the speed of margin recovery visible in Q1 FY2026 — and the possibility that the market is pricing permanent damage to a cyclical problem. Watch Q2 FY2026 Medicaid HBR and Marketplace membership retention to determine whether the base case holds or the bear case materializes.

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — CNC's Q1 FY2026 earnings beat and 16% FCF yield create a compelling risk/reward if Medicaid margin recovery sustains through Q2-Q3, but the OBBBA's structural impact on Medicaid membership and Marketplace contraction from expired APTCs introduce genuine uncertainty about normalized earnings power. The tension that matters most is whether Medicaid HBR improvement is cyclical recovery (bull wins) or a brief respite before OBBBA-driven morbidity deterioration overwhelms rate increases (bear wins). Two more quarters of Medicaid HBR below 93.5% would shift this verdict to Lean Long with conviction.

Bull Case

Bull's price target: $90, derived from 15x P/E on $6.00 normalized EPS (FY2027E). Timeline: 18-24 months. Primary catalyst: sustained Medicaid HBR improvement through Q2-Q3 FY2026. Disconfirming signal: Medicaid HBR reverses above 94% for two consecutive quarters.

Bear Case

Bear's downside target: $30, derived from 10x P/E on $3.00 adjusted EPS in a scenario where membership declines accelerate and margins fail to normalize. Timeline: 12-18 months. Primary trigger: Medicaid HBR reverses above 94% with accelerating membership loss. Cover signal: two consecutive quarters of Medicaid HBR below 92%.

The Real Debate

Verdict

Verdict: Lean Long, Wait For Confirmation. The bull case carries more weight because Q1 FY2026 delivered concrete evidence of margin recovery — not guidance, not promises, but a $0.50 earnings beat with improving Medicaid HBR. The 16% FCF yield provides a substantial margin of safety even if normalized earnings land at $4-5 rather than $6-7. The most important tension is whether the Medicaid HBR improvement is durable through the OBBBA implementation period. The bear is right that structural Medicaid membership erosion and Marketplace contraction are real — these are not cyclical headwinds but permanent policy shifts. However, the bear's case requires that rate inadequacy persists, and the evidence from Q1 FY2026 (composite rate yield of 4.5%, HBR improving for three consecutive quarters) suggests rates are in fact catching up. The condition that would change this verdict to Avoid: Medicaid HBR reversal above 94% combined with loss of Georgia or Texas Medicaid contracts, which would signal both margin and membership deterioration simultaneously.

The People

Governance grade: B. Sarah London inherited a company in crisis after founder Michael Neidorff's death in November 2022 and has stabilized operations, cut SG&A by 110bp, and begun portfolio rationalization (Magellan divestitures). The main concern is thin insider ownership relative to company size and the aggressive buyback program that continued through margin deterioration. The board is refreshed and independent but lacks deep managed care operating experience.

The People Running This Company

Sarah London took over after Neidorff's death, becoming CEO at 39 — young for a $100B+ revenue company. Her track record: stabilized the company through the Medicaid redetermination wave, drove SG&A from 8.5% to 7.4%, divested non-core assets (Circle Health, Magellan Rx, Magellan Specialty Health, CHS), and repriced 95% of Marketplace business in Q3 2025 when utilization spiked. The Q1 FY2026 earnings beat and guidance raise validate her operational credibility.

The April 2026 leadership restructure — hiring Dan Finke (former Aetna President) for Medicaid/Commercial and elevating Michael Carson for Medicare/Specialty — signals a shift from crisis management to growth execution.

What They Get Paid

London's $20.6M total compensation (per external data) is reasonable for a Fortune 25 company CEO — UNH's Andrew Witty earned $23.5M in his final year. The 93% equity weighting creates alignment, though the performance conditions on London's options (stock must close at or above $100 for 20 consecutive trading days) are currently deeply out of the money at $53.69. This creates a strong incentive to drive stock recovery but also raises questions about whether management might take excessive risk.

The 2022 proxy introduced adjusted net earnings margin metrics to align management incentives with the margin expansion strategy — an appropriate response to stockholder feedback.

Are They Aligned?

CEO London's August 2025 open-market purchase at $25.50 — buying 19,230 shares near the 52-week low of $25.21 — is the most meaningful insider signal. She put personal capital at risk when the stock was at its nadir following the goodwill impairment announcement. The stock has since doubled to $53.69.

The buyback program deserves scrutiny: $7.9B in FY2022-2024 was funded partly by operating cash flow and partly by maintaining high debt levels. In hindsight, buying back stock at $70-80 while the business faced margin pressure was aggressive. Management corrected in FY2026 by suspending buybacks entirely and directing cash to debt reduction ($1.9B repaid in FY2025).

Skin-in-the-game score: 6/10. London's direct ownership is thin (0.052%), but the open-market buy, heavy equity compensation weighting, and buyback suspension at the right time show rational capital allocation instincts.

Board Quality

The board was substantially refreshed in 2021-2022 — six of nine directors joined within two years, addressing governance concerns from the Neidorff era. Gender and ethnic diversity reached 43%. Chairman Eppinger (Stewart Information Services CEO) brings insurance industry perspective.

Strengths: High independence (8 of 9 independent), recent refreshment eliminates founder-era entrenchment, audit committee led by former Deloitte Vice Chairman (Blume), strong financial expertise (two former Fortune 500 CFOs).

Weaknesses: Only Burdick has direct managed care operating experience (former WellCare CEO). No current hospital system executive or physician on the board for a company managing healthcare for 28M people. Two technology-focused directors (Dallas, Ford) but unclear how their expertise translates to managed care operations.

The Verdict

Grade: B. London has proven capable under fire — navigating the post-Neidorff transition, Medicaid redeterminations, the goodwill impairment, and multiple divestitures. The Q1 FY2026 beat and raised guidance are tangible evidence of execution. The board is refreshed, independent, and competent but could use more managed care depth.

Strongest positives: CEO open-market buy at the low, SG&A discipline (7.4% ratio), rational buyback suspension in FY2026, clean leadership restructure with experienced hires (Finke from CVS/Aetna).

Real concerns: thin direct CEO ownership, $7.9B in buybacks during FY2022-2024 when margins were under pressure looks like poor timing, and the board lacks deep managed care expertise beyond Burdick.

What would upgrade the grade: London or other executives making additional open-market purchases above $50, successful Magellan divestiture closing at reasonable terms, and Medicaid HBR improving to under 92% for two consecutive quarters.